Answers are grounded in this paper and cite their sources.
Although the median age for adults with acute lymphoblastic leukemia (ALL) is older than 60 years, relatively few of these patients have been enrolled on prospective clinical trials. The presence of coexisting medical disorders and unfavorable cytogenetic and biological characteristics within this population presents considerable challenges for successful treatment using conventional chemotherapy programs. Selected patients have achieved remission and long-term survival following intensive chemotherapy. Preliminary data using several new agents that have shown promise for patients with ALL are described.
No takes yet. Share an insight, caveat, or question.
Richard A. Larson (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: